tetano
Editor, Senior Moderator
J Emerg Med
. 2020 Dec 11;S0736-4679(20)31354-8.
doi: 10.1016/j.jemermed.2020.12.005. Online ahead of print.
Vaping-Associated Lung Injury During COVID-19 Multisystem Inflammatory Syndrome Outbreak
Ameer Hassoun[SUP] 1 [/SUP], KeriAnne Brady[SUP] 1 [/SUP], Rojin Arefi[SUP] 1 [/SUP], Irina Trifonova[SUP] 2 [/SUP], Kalliope Tsirilakis[SUP] 3 [/SUP]
Affiliations
Abstract
Background: E-cigarette or vaping product use-associated lung injury (EVALI) is a complex inflammatory syndrome predominantly seen in adolescents and young adults. The clinical and laboratory profile can easily mimic infectious and noninfectious conditions. The exclusion of these conditions is essential to establish the diagnosis. Recently, the novel coronavirus disease 2019 (COVID-19) pandemic introduced the multisystem inflammatory syndrome in children (MIS-C). MIS-C knowledge is evolving. The current criteria to establish the diagnosis are not specific and have overlapping features with EVALI, making the accurate diagnosis a clinical challenge during continued COVID-19 transmission within the community.
Case report: Three young adults evaluated at our emergency department for prolonged fever and gastrointestinal and respiratory symptoms were initially assessed for possible MIS-C due to epidemiologic links to COVID-19 and were eventually diagnosed with EVALI. The clinical, laboratory, and radiologic characteristics of both entities are explored, as well as the appropriate medical management. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Physician awareness of overlapping and differentiating EVALI and MIS-C features is essential to direct appropriate diagnostic evaluation and medical management of adolescents and young adults presenting with systemic inflammatory response during the unfolding pandemic of COVID-19.
Keywords: E-cigarette or vaping product use-associated lung injury; multisystem inflammatory syndrome in children; novel coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2.
. 2020 Dec 11;S0736-4679(20)31354-8.
doi: 10.1016/j.jemermed.2020.12.005. Online ahead of print.
Vaping-Associated Lung Injury During COVID-19 Multisystem Inflammatory Syndrome Outbreak
Ameer Hassoun[SUP] 1 [/SUP], KeriAnne Brady[SUP] 1 [/SUP], Rojin Arefi[SUP] 1 [/SUP], Irina Trifonova[SUP] 2 [/SUP], Kalliope Tsirilakis[SUP] 3 [/SUP]
Affiliations
- PMID: 33483200
- PMCID: PMC7732222
- DOI: 10.1016/j.jemermed.2020.12.005
Abstract
Background: E-cigarette or vaping product use-associated lung injury (EVALI) is a complex inflammatory syndrome predominantly seen in adolescents and young adults. The clinical and laboratory profile can easily mimic infectious and noninfectious conditions. The exclusion of these conditions is essential to establish the diagnosis. Recently, the novel coronavirus disease 2019 (COVID-19) pandemic introduced the multisystem inflammatory syndrome in children (MIS-C). MIS-C knowledge is evolving. The current criteria to establish the diagnosis are not specific and have overlapping features with EVALI, making the accurate diagnosis a clinical challenge during continued COVID-19 transmission within the community.
Case report: Three young adults evaluated at our emergency department for prolonged fever and gastrointestinal and respiratory symptoms were initially assessed for possible MIS-C due to epidemiologic links to COVID-19 and were eventually diagnosed with EVALI. The clinical, laboratory, and radiologic characteristics of both entities are explored, as well as the appropriate medical management. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Physician awareness of overlapping and differentiating EVALI and MIS-C features is essential to direct appropriate diagnostic evaluation and medical management of adolescents and young adults presenting with systemic inflammatory response during the unfolding pandemic of COVID-19.
Keywords: E-cigarette or vaping product use-associated lung injury; multisystem inflammatory syndrome in children; novel coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2.